['metastatic renal cell carcinoma']
['testosterone undecanoate and sunitinib or pazopanib']

        Inclusion Criteria:

          1. Histologically proven clear cell renal cell carcinoma;

          2. CT-confirmed metastatic measurable disease;

          3. First-line sunitinib or pazopanib treatment with fatigue;

          4. Low level of testosterone;

        4. Male, 18 years and older; 5. Normal PSA level

        Exclusion Criteria:

          1. Prostate and other cancers history

          2. Hypothyroidism

          3. History of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or
             other severe cardiovascular disease (i.e., New York Heart Association class III or IV)
      